Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
2018
The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
48
References
0
Citations
NaN
KQI